Browse
Submit Data
Databases
API
Help

Dataset Information

13 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The effect of dexmedetomidine on perioperative cholinergic anti-inflammatory pathway and the balance of Th17 / Treg in colorectal cancer patients

ABSTRACT: Interventions: DEX: a loading dosage of dexmedetomidine (0.5 ug/Kg) was infused introvenously 10 min before anesthesia and followed continously at0.5 ug/Kg/h for 2h;control:saline Primary outcome(s): interleukin-17, 6, 23, 10, 1ß, TNF-a, TGFß-1, HMGB1, Th17/Treg cell count Study Design: Randomized parallel controlled trial

DISEASE(S): Colorectal Cancer

PROVIDER: 2663054 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Effects of different doses of dexmedetomidine on postoperative analgesia, sleep and gastrointestinal function in patients with colorectal cancer

Project description:Interventions: DEX 1 group:DEX 200 ug uesd for PCIA;DEX 2 group:DEX 400 ug used for PCIA;DEX 0 group:DEX 0 ug/kg/h uesd for PCIA Primary outcome(s): gastrointestinal function recovery;sleep disorder Study Design: Dose comparison

| 2693064 | ecrin-mdr-crc

Effects of dexmedetomidine combined with epidural anesthesia on intestinal function and postoperative outcomes of patients undergoing laparoscopic colorectal cancer surgery

Project description:Interventions: Control group (CON group):Intravenous and inhalation combined anesthesia, equal amount of normal saline; Sufentanil PCIA.;Dexmedetomidine group (DEX group):Dexmedetomidine group (DEX group): intravenous anesthesia was assisted by intravenous of DEX with the loading dose of 0.5~1.0 microgram/kg completed within 10 minutes and maintenance infusion of 0.5~1.0 microgram /kg/h until the end of the operation. Sufentanil + DEX to implement PCIA.; Epidural group (EP group):Intravenous Inhalation Combined with epidural anesthesia, ropivacaine + sufentanil PCEA;DEX + EP group:Intravenous anesthesia assisted by intravenous DEX combined with epidural anesthesia, ropivacaine + DEX PCEA. Primary outcome(s): Peristalsis time after operation;Oral feeding time after operation Study Design: Parallel

| 47743 | ecrin-mdr-crc

Proteomic results of Lactobacillus plantarum P8 alleviating dexamethasone-induced oxidative stress in broiler liver

Project description:The broilers were randomly allotted to four treatment groups (Con, DEX, P8, and DEX+P8 groups) with 10 replicates per group (10 broilers per replicate). Broilers in the Con and DEX groups were fed a basal diet. Broilers in the P8 and DEX+P8 groups were fed a basal diet containing 1 × 108 CFU/g P8. At 16 days of age, broilers in the DEX and DEX+P8 groups were injected with 3 mg/kg body weight DEX (200 μL), whereas broilers in the Con group were injected with an equal volume of saline.

2023-02-24 | PXD040369 | iProX

Optimization of HUNTER N-termini profiling using rat brain proteome extracts

Project description:Optimization hydrophobic tagging reaction time (30 min to 2h) and evaluation of the HUNTER protocol performance with different amounts (25 ug to 400 ug) of purified rat brain proteome as starting material.

2019-09-03 | PXD012844 | Pride

The H3K4me3 pattern of mouse renal cortex tissues treated with dexmedetomidine against lipopolysaccharide-induced sepsis

Project description:Dexmedetomidine (DEX) was served to controlling the over-reactive inflammatory effects to protect from the sepsis-induced organ failure via modulating histone methylation. However, the genome-wide changes of histone methylations upon DEX for sepsis treatment were poorly explored. (AKI) mouse model was induced by lipopolysaccharide (LPS), and added DEX (AKI+D) and KDM5A-IN-1 (KDM5A inhibitor) (AKI+K) respectively. ChIP-seq to investigate the H3K4me3 pattern in renal cortex tissues. Each group has two replications.

2020-07-03 | E-MTAB-8133 | biostudies-arrayexpress

Effects of atomized Esketamine combined with dexmedetomidine on postoperative pharyngalgia and perioperative stress response in patients with colorectal cancer

Project description:Interventions: Blank control group:Preoperative atomization of 5ml normal saline;Esketamine group:Preoperative atomization inhalation of 0.5mg/kg Esketamine plus normal saline to prepare 5ml;Dexmedetomidine group:Atomized inhalation of 1 ug/kg dexmedetomidine plus physiological saline is 5 ml;Dexmedetomidine combined with esketamine group:Atomized inhalation of 0.25mg/kg esketamine +0.5ug/kg dexmedetomidine plus normal saline was configured as 5ml 30min before surgery Primary outcome(s): Incidence of postoperative sore throat Study Design: Parallel

| 88491 | ecrin-mdr-crc

Coordinated regulation of transcription by CcpA and the Staphylococcus aureus two component system HptRS

Project description:Total cytosolic protein fractions of Staphylococcus aureus strains SA564, SA564-ΔhptRS, SA564-ΔccpA and SA564-ΔhptRS/ccpA were analyzed by LC-MSE . Five biological replicates of each strain, cultivated in TSB and TSB-dex, during the exponential (2h) and post exponential (6h) growth phases (80 samples) were investigated.

2018-12-19 | PXD008708 | Pride

Effect of Dexmedetomidine on ncRNA and mRNA Profiles of Cerebral Ischemia-Reperfusion Injury in Transient Middle Cerebral Artery Occlusion Rats Model

Project description:Ischemic stroke poses a significant global health burden, with rapid revascularization treatments being crucial but often insufficient to mitigate ischemia-reperfusion (I/R) injury. Dexmedetomidine (DEX) has shown promise in reducing cerebral I/R injury, but its potential molecular mechanism, particularly its interaction with non-coding RNAs (ncRNAs), remains unclear. This study investigates DEX's therapeutic effect and potential molecular mechanisms in reducing cerebral I/R injury. A transient middle cerebral artery obstruction (tMACO) model was established to simulate cerebral I/R injury in adult rats. DEX was administered pre-ischemia and post-reperfusion. RNA sequencing and bioinformatic analyses were performed on the ischemic cerebral cortex to identify differentially expressed non-coding RNAs (ncRNAs) and mRNAs. The sequencing results showed 6494 differentially expressed (DE) mRNA and 2698 DE circRNA between the sham (S) and tMCAO (I/R) groups. Additionally, 1809 DE lncRNA, 763 DE mRNA, and 2795 DE circRNA were identified between the I/R group and tMCAO+DEX (I/R+DEX) groups. Gene ontology (GO) analysis indicated significant enrichment in multicellular biogenesis, plasma membrane components, and protein binding. KEGG analysis further highlighted the potential mechanism of DEX action in reducing cerebral I/R injury, with hub genes involved in inflammatory pathways. This study demonstrates DEX's efficacy in reducing cerebral I/R injury and offers insights into its brain-protective effects, especially in ischemic stroke. Further research is warranted to fully understand DEX's neuroprotective mechanisms and its clinical applications.

2024-07-27 | GSE268634 | GEO

Effects of ACTH and DEX on gene expression in rat kidneys

Project description:The left kidneys of 8 Sprague-Dawley rats were removed and the rats were left for 2 weeks to recover. After 4 additional days (during which blood pressure measurements were obtained), they were injected daily subcut. with either saline (1ml/kg), adrenocorticotropic hormone (ACTH, 0.2mg/kg) or dexamethasone (DEX, 0.02mg/kg) for 8 days before the right kidney was removed. ACTH and DEX treatment caused hypertension in the rats as illustrated by increased systolic blood pressure. The gene expression patterns of the kidneys were analysed using Affymetrix arrays. Keywords: repeat

2007-11-01 | GSE6216 | GEO

Effect of CWG-cPIP on transcriptome defects in CUG mouse brain

Project description:CWG-cPIP targets CAG/CTG (CWG) triplet repeat DNA to inhibit the transcription in a repeat length-dependent manner. To investigate effects of CWG-cPIP on transcriptome defects in the brain of CUG300 mice, which we developed as a model of DM1, CWG-cPIP (83 ug/kg) was injected into mouse hippocampus. RNA sequencing analysis was performed using mouse hippocampus 10 days later.

2023-10-11 | GSE210838 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data